Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Texas Southwestern Medical Center
About this trial
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
Eligibility criteria
Qualifiers
Patients must have metastatic ccRCC.
Patients must have oligoprogression defined as progression in ≤5 lesions.
All oligoprogression lesions must be suitable for radiation.
Patients must have at least one site of disease that can be safely injected with IMSA101.
Disqualifiers
Patients with progressive ultracentral/central chest lesions will be excluded
Trial design
Treatments tested in this trial
- IMSA101
Treatment groups
15 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov